SANES

10.768

+1.24%↑

BBVA

20.05

+1.26%↑

BNP

92.46

+0.97%↑

CABK

11.66

+0.43%↑

INGA

27.145

+1.51%↑

SANES

10.768

+1.24%↑

BBVA

20.05

+1.26%↑

BNP

92.46

+0.97%↑

CABK

11.66

+0.43%↑

INGA

27.145

+1.51%↑

SANES

10.768

+1.24%↑

BBVA

20.05

+1.26%↑

BNP

92.46

+0.97%↑

CABK

11.66

+0.43%↑

INGA

27.145

+1.51%↑

SANES

10.768

+1.24%↑

BBVA

20.05

+1.26%↑

BNP

92.46

+0.97%↑

CABK

11.66

+0.43%↑

INGA

27.145

+1.51%↑

SANES

10.768

+1.24%↑

BBVA

20.05

+1.26%↑

BNP

92.46

+0.97%↑

CABK

11.66

+0.43%↑

INGA

27.145

+1.51%↑

Inicio・Lista de Acciones・DBV Technologies SA

D
DBV Technologies SA

Cerrado

3.312 4.15

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

3.18

Máximo

3.354

Métricas clave
By Trading Economics
Ingresos	-2.4M -48M
BPA	-0.095
Margen de beneficios	-1,323.179
Empleados	161
EBITDA	-4.1M -46M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	+2.52% upside

Dividendos
By Dow Jones
Próximas Ganancias	29 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-70M 969M
Apertura anterior	-0.84
Cierre anterior	3.312

DBV Technologies SA Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

25 may 2026, 08:24 UTC

Principales Movimientos del Mercado

Adquisiciones, fusiones, absorciones

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 may 2026, 21:22 UTC

Ganancias

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 may 2026, 20:50 UTC

Charlas de Mercado

Ganancias

Basic Materials Roundup: Market Talk

25 may 2026, 16:20 UTC

Charlas de Mercado

Ganancias

Basic Materials Roundup: Market Talk

25 may 2026, 16:01 UTC

Charlas de Mercado

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 may 2026, 14:43 UTC

Charlas de Mercado

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 may 2026, 14:15 UTC

Charlas de Mercado

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 may 2026, 13:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

25 may 2026, 12:58 UTC

Charlas de Mercado

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 may 2026, 12:56 UTC

Charlas de Mercado

Ganancias

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 may 2026, 12:48 UTC

Charlas de Mercado

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 may 2026, 12:48 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

25 may 2026, 12:34 UTC

Charlas de Mercado

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 may 2026, 12:10 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Delivery Hero's Assets Look Strategic -- Market Talk

25 may 2026, 11:00 UTC

Charlas de Mercado

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 may 2026, 10:19 UTC

Charlas de Mercado

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 may 2026, 10:05 UTC

Ganancias

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 may 2026, 10:04 UTC

Ganancias

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 may 2026, 10:03 UTC

Ganancias

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 may 2026, 10:02 UTC

Ganancias

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 may 2026, 10:01 UTC

Ganancias

Tenaga Nasional 1Q Net Up 3.7% on Year

25 may 2026, 10:00 UTC

Ganancias

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 may 2026, 09:56 UTC

Ganancias

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 may 2026, 09:56 UTC

Ganancias

Tenaga Nasional 1Q EPS MYR0.1883

25 may 2026, 09:56 UTC

Ganancias

Tenaga Nasional 1Q Rev MYR17.1B

25 may 2026, 09:56 UTC

Ganancias

Tenaga Nasional 1Q Net MYR1.1B

25 may 2026, 09:38 UTC

Charlas de Mercado

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 may 2026, 09:33 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

25 may 2026, 09:33 UTC

Charlas de Mercado

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 may 2026, 08:55 UTC

Charlas de Mercado

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Comparación entre iguales

Cambio de precio

DBV Technologies SA previsión

Precio Objetivo

By TipRanks

2.52% repunte

Estimación a 12 Meses

Media 3.26 EUR 2.52%

Máximo 5.5 EUR

Mínimo 1.01 EUR

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para DBV Technologies SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para DBV Technologies SA Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de DBV Technologies SA

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.